NCT01118910

Brief Summary

The purpose of this study is to determine if people with moist, red, patches on their skin in body folds would benefit treatment of those areas with an FDA-approved drug called Vusion.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at P25-P50 for early_phase_1

Timeline
Completed

Started Apr 2010

Shorter than P25 for early_phase_1

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2010

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

May 6, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

May 7, 2010

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2010

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2011

Completed
Last Updated

August 4, 2011

Status Verified

August 1, 2011

Enrollment Period

7 months

First QC Date

May 6, 2010

Last Update Submit

August 3, 2011

Conditions

Keywords

IntertrigoVusion

Outcome Measures

Primary Outcomes (1)

  • The number of patients for whom Vusion effectively treated intertrigo

    3 months

Study Arms (1)

Vusion ointment

EXPERIMENTAL
Drug: Vusion

Interventions

VusionDRUG

Vusion will be applied to areas of intertrigo

Vusion ointment

Eligibility Criteria

Age12 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Evidence of intertrigo

You may not qualify if:

  • Pregnancy
  • Use of systemic or topical antifungal or corticosteroid treatment in the previous 14 days or during the 3-month treatment period
  • allergy of sensitivity to Vusion
  • undergoing warfarin anticoagulation
  • alcohol or drug abuse
  • Investigator determines they cannot particpate
  • history of non-compliance or poor cooperation
  • participation in an investigaitonal drug study within 30 days of Baseline Visit

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Image Dermatology P.C.

Montclair, New Jersey, 07042, United States

Location

MeSH Terms

Conditions

Intertrigo

Condition Hierarchy (Ancestors)

DermatitisSkin DiseasesSkin and Connective Tissue DiseasesSkin Diseases, Eczematous

Study Officials

  • Jeanine B. Downie, M.D.

    Image Dermatology P.C.

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

May 6, 2010

First Posted

May 7, 2010

Study Start

April 1, 2010

Primary Completion

November 1, 2010

Study Completion

May 1, 2011

Last Updated

August 4, 2011

Record last verified: 2011-08

Locations